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Introduction
Adipose tissue depots in both humans and rodents perform a 
remarkable spectrum of contrasting functions, including seques-
tration of excess caloric energy in the form of triglyceride in white 
adipose tissue (WAT) and rapid conversion of oxidative energy to 
heat for survival in the cold in brown adipose tissue (BAT). Vari-
ous fat depots also secrete specific signature profiles of proteins 
and other factors that play key roles in overall systemic energy 
metabolism and glucose homeostasis (1). A general paradigm in 
the field is that 2 major opposing hormone systems, insulin (Ins) 
and catecholamines, are prominent regulators of these adipocyte 
functions. The catecholamines norepinephrine and epinephrine 
activate β-adrenergic receptors (βARs) to increase cAMP levels 
and cAMP-dependent protein kinase A (PKA) activity. PKA phos-
phorylates and regulates several important targets in adipocytes, 
including hormone-sensitive lipase and the lipid droplet–associ-
ated perilipins, which collectively promote triglyceride hydrolysis 
and liberation of free fatty acids (2–4). The opposing metabolic 
regulator is Ins, which antagonizes the action of the catechola-
mines to stimulate lipolysis by activating phosphodiesterases 
that degrade cAMP (5) and by activating lipid synthesis pathways 
through actions of the protein kinase AKT (6).
Signaling by catecholamines to stimulate lipolysis in WAT pro-
vides fatty acid substrates to fuel peripheral tissues, while, in BAT, 
lipolysis provides fatty acid substrates for generating heat. Brown 
adipocytes are highly enriched in mitochondria and express the 
unique protein uncoupling protein-1 (UCP1), which “uncouples” the 
mitochondrial proton gradient from adenosine triphosphate (ATP) 
production during fatty acid oxidation to produce thermal energy 
(7). The result is net energy expenditure. UCP1-containing “brown-
like” adipocytes can also be recruited within WAT depots through 
prolonged βAR stimulation of lipolysis (8, 9) and are called “brite” or 
“beige” adipocytes (10, 11). Studies using mouse models show that 
the increase in these beige adipocytes closely correlates with resis-
tance to obesity (12, 13), and in humans, the amount of detectable 
brown/beige adipocytes is significantly correlated with reduced 
percent body fat and circulating triglycerides, as well as greater Ins 
sensitivity (14–21). As with lipolysis, where Ins opposes the actions of 
βARs, Ins also appears to antagonize catecholamine stimulation of 
adipose browning (22) secondary to its suppression of lipolysis.
A major signaling node for the anabolic actions of Ins that 
strongly promote lipogenesis and protein synthesis downstream 
of AKT are the mTOR complexes. mTOR is a 250 kDa conserved 
Ser/Thr kinase that regulates cell growth and metabolism in 
response to environmental cues such as growth factors and nutri-
ents, in addition to Ins (23). There are 2 structurally and func-
tionally distinct mTOR-containing protein complexes, mTORC1 
and mTORC2, required for activation of AKT (24–26). A defin-
ing characteristic of mTORC1 is its inhibition by the macrolide 
antibiotic rapamycin (26, 27), and it contains the partner protein 
RAPTOR (regulatory-associated protein of mTOR). By contrast, at 
least acutely, mTORC2 is not directly affected by rapamycin, and 
it contains the partner protein RICTOR (rapamycin-insensitive 
companion of mTOR). A well-characterized downstream target of 
mTORC1, but not mTORC2, is p70 ribosomal S6 kinase 1 (S6K1), 
which is thus highly activated by Ins.
A classic metabolic concept posits that insulin promotes energy storage and adipose expansion, while catecholamines 
stimulate release of adipose energy stores by hydrolysis of triglycerides through β-adrenergic receptor (βARs) and protein 
kinase A (PKA) signaling. Here, we have shown that a key hub in the insulin signaling pathway, activation of p70 ribosomal S6 
kinase (S6K1) through mTORC1, is also triggered by PKA activation in both mouse and human adipocytes. Mice with mTORC1 
impairment, either through adipocyte-specific deletion of Raptor or pharmacologic rapamycin treatment, were refractory 
to the well-known βAR-dependent increase of uncoupling protein UCP1 expression and expansion of beige/brite adipocytes 
(so-called browning) in white adipose tissue (WAT). Mechanistically, PKA directly phosphorylated mTOR and RAPTOR on 
unique serine residues, an effect that was independent of insulin/AKT signaling. Abrogation of the PKA site within RAPTOR 
disrupted βAR/mTORC1 activation of S6K1 without affecting mTORC1 activation by insulin. Conversely, a phosphomimetic 
RAPTOR augmented S6K1 activity. Together, these studies reveal a signaling pathway from βARs and PKA through mTORC1 
that is required for adipose browning by catecholamines and provides potential therapeutic strategies to enhance energy 
expenditure and combat metabolic disease.
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with phosphorylation of RAPTOR by PKA prevents activation of 
S6K1 by β-agonists, without affecting its stimulation by Ins. These 
findings illustrate the existence of a new signaling pathway from 
PKA to mTORC1 and its requirement for the sympathetic nervous 
system–driven (SNS-driven) recruitment and expansion of the 
UCP1-containing beige cells in WAT.
Results
βAR agonists activate mTORC1 in adipocytes
During preliminary studies comparing the effects of Ins and βAR 
agonists on signal transduction and metabolism in adipocytes, we 
observed that when 3T3-L1 adipocytes were treated with the nonse-
lective βAR agonist isoproterenol (Iso), S6K1 became phosphorylated, 
which is best known to be activated by Ins. We then compared the abil-
Ins activation of mTOR would suggest that catecholamines 
may oppose this action and inhibit this complex. Indeed, data 
showing that the cAMP pathway can inhibit mTOR exists not only 
in adipocytes (28, 29), but also in other cells such as lymphoblasts 
(30) and smooth muscle cells (31, 32). However, catecholamine 
action to increase the abundance of beige adipocytes within WAT 
entails increased biosynthetic capacity, including enhanced mito-
chondrial and cell protein mass, for which mTOR1 is a central 
player. We therefore further investigated this connection and show 
here that β-adrenergic stimulation activates the mTORC1/S6K1 
pathway. Remarkably, we found that βAR-mediated browning of 
white adipose depots in mice requires the activation of mTORC1 
and S6K1 through a mechanism that is distinct from that of Ins and 
growth factors. Specifically, both mTOR and the mTORC1 com-
ponent RAPTOR can be phosphorylated by PKA, and interference 
Figure 1. βAR activation of mTORC1 in 
adipocytes. (A–C) 3T3-L1 adipocytes were 
pretreated or not with rapamycin (Rapa, 
100 nM) for 30 minutes prior to the 
addition of Iso (1 μM) or Ins (10 nM) for 1 
hour (A); HIB-1B brown adipocytes were 
pretreated or not with rapamycin. Iso 
was added for 1 hour (B); Human primary 
s.c. adipocytes were treated or not with 
Rapa for 30 minutes, followed by Iso for 
1 hour (C), and levels of phosphorylated, 
total S6K1, and internal control GAPDH 
were measured by Western blotting. Bar 
graphs show image quantification of 
p-S6K1 normalized to total S6K1 (n = 3). 
One-way ANOVA followed by post-hoc 
comparisons. C, control. *P < 0.05,  
**P < 0.01.
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AKT-dependent pathway (33). We compared signaling events mediat-
ing S6K1 activation in response to Iso versus Ins in 3T3-L1 adipocytes. 
As shown in Figure 2A, Ins (10 nM) increased phosphorylation of AKT 
(Thr308, Ser473) and S6K1 (Thr389), as established by others (6, 34). Phos-
phorylation of S6K1 by Ins was fully suppressed by rapamycin. In con-
trast to Ins, Iso activated S6K1 but did not trigger phosphorylation of 
AKTT308 or AKTS473 (Figure 2B). In addition, proline-rich AKT substrate 
40 (PRAS40) was phosphorylated by Ins treatment but not by Iso. We 
also observed that GSK3α and -β were phosphorylated by either Ins or 
Iso, which was unaffected by rapamycin. ULK1, another established 
mTORC1 target (35), was also activated by both Ins and Iso. To fur-
ther confirm the activation of mTORC1 by Iso, the pan-mTOR inhib-
itor torin1 (36) blocked both Iso- and Ins-stimulated S6K1 activation 
(Supplemental Figure 4). We also found that rapamycin treatment 
in L1 adipocytes did not affect Iso-mediated lipolysis (Supplemental 
Figure 5). Considering that G protein–coupled receptors including 
βARs can also activate MAPKs such as ERK and p38 MAPK (37–41), 
we examined these pathways. As shown in Figure 2, C and D, the MEK 
inhibitor PD98059 (PD) and the p38 MAPK inhibitor SB202190 (SB) 
fully blocked activation of their respective kinases following Iso stim-
ulation, but these inhibitors had no effect on Iso-mediated S6K1 phos-
ity of Ins and Iso to activate S6K1 in adipocytes. As shown in Figure 1A, 
Ins was more potent than Iso in mediating this effect, while rapamy-
cin, an inhibitor of mTORC1, blocked the actions of both agents. Phos-
phorylation of S6K1 in response to Iso was both potent (≤10 nM) and 
brisk (≤10 minutes) (Supplemental Figure 1, A and B; supplemental 
material available online with this article; doi:10.1172/JCI83532DS1) 
and was mediated by all 3 βARs in adipocytes (Supplemental Figure 
1, C–F). The ability of βARs to activate S6K1 is also observed in mouse 
brown adipocytes (Figure 1B), as well as in human primary s.c. adipo-
cytes (Figure 1C). In addition, treatment of cells with the direct ade-
nylyl cyclase activator forskolin (Fsk) increased S6K1 phosphorylation 
(Supplemental Figure 2A). Therefore, although Ins and β-adrenergic 
agents classically serve opposing roles in adipocytes for managing 
metabolic fuel usage, including an antagonistic role of cAMP to blunt 
Ins-stimulated mTORC1 (Supplemental Figure 3), they are both capa-
ble of activating mTORC1.
mTORC1 activation by βARs depends on PKA
Next, we used a set of in vitro approaches to gain insight into the molec-
ular signaling events connecting βAR activation and mTORC1. It is 
well known that Ins and growth factors activate mTORC1 through an 
Figure 2. βAR activation of S6K1 in 
adipocytes is PKA dependent, and 
independent of AKT. (A and B) 3T3-L1 
adipocytes were pretreated or not with 
Rapa for 30 minutes followed by either 
Ins (A) or Iso (B) for 1 hour, and levels of 
total and phosphorylated AKT, PRAS40, 
S6K1, ULK1, and GSK3 in lysates were 
measured by Western blotting. (C) 
3T3-L1 adipocytes were treated with the 
following kinase inhibitors for 30 min: 
PKA inhibitor H89 (20 μM), MEK inhibitor 
PD (40 μM), and p38α/β inhibitor SB (20 
μM), followed by Iso (1 μM). The addition 
of 10% FBS to medium for 1 hr served as 
a positive control to confirm activation 
of S6K1 and ERK by growth factors. Cell 
lysates were prepared, and total and 
phospho-S6K1, ERK, and p38 MAPKs 
were measured by immunoblot. (D) Bar 
graphs show image quantification of 
p-S6K1 normalized to total S6K1 of  
n = 3 experiments from C. One-way 
ANOVA followed by post-hoc group com-
parisons; *P < 0.05.
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with rapamycin or vehicle for 48 hours prior to the cold (4°C) expo-
sure. There was a dramatic increase in S6 phosphorylation in inter-
scapular BAT (iBAT) (Figure 3A) and in s.c. inguinal WAT (iWAT) 
(Figure 3B). In mice that were pretreated with rapamycin, this 
phosphorylation was fully blocked. Similar results were observed in 
gonadal WAT (gWAT; not shown). Figure 3C shows that core body 
temperature dropped slightly in both groups as expected, but after 
7 hours, the rapamycin-treated group exhibited a further decline 
in temperature, which became significant by 10 hours. At this time 
point, UCP1 protein level in iBAT tended to be lower with rapamy-
cin treatment, with no effect on Ins signaling as measured by AKT 
phosphorylation (Supplemental Figure 6). However, given the 
whole-body exposure to rapamycin, this temperature change can-
not be ascribed specifically to adipose tissue. In general, during this 
phorylation. Only the PKA inhibitors H89 (Figure 2C) and KT5720 
(Supplemental Figure 2B) blocked Iso-induced S6K1 activation, sug-
gesting that PKA itself, and not these other downstream kinases, is 
responsible for βAR-stimulated mTORC1-S6K1 activation.
mTORC1 activity contributes to white adipose browning
Cold-temperature challenge. A cold-temperature challenge is a classic 
maneuver that triggers an increase in SNS outflow to tissues includ-
ing white and brown fat and generates heat from stored energy 
(42–45). When placed in a cold environment, mice exhibit a mod-
erate decrease in core body temperature within the first few hours, 
followed by a temperature plateau. In this early phase, the animal 
generates heat largely through muscle shivering, which is followed 
by nonshivering thermogenesis (NST) in BAT (7). Mice were treated 
Figure 3. Elevating SNS activity via cold exposure activates mTORC1 signaling in BATs and WATs. Male mice (n = 5/group) received either vehicle or 
rapamycin (Rapa; 4 mg/kg BW) by i.p. injection for 2 days followed by exposure to 4°C or 23°C for 6 hrs. (A and B) iBAT (A) and iWAT (B) were collected, 
homogenized, and assayed by immunoblot for p-S6 and total S6. GAPDH served as an internal control. Bar graphs show image quantification of p-S6 
normalized to total S6. One-way ANOVA followed by post-hoc group comparisons; **P < 0.01. (C) Core body temperature was monitored and recorded 
for vehicle- or Rapa-treated mice during cold exposure. One-way ANOVA followed by post-hoc Bonferroni analysis. **P < 0.01. (D) iBAT and iWAT were 
dissected from cold-acclimated mice receiving either vehicle or Rapa for immunoblotting detection of UCP1 and internal-control GAPDH. (E) Core body 
temperature was recorded for vehicle- or Rapa-treated mice during cold adaptation (n = 4). C, control. One-way ANOVA followed by post-hoc Bonferroni 
analysis. *P < 0.05.
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vs. 4°C rapamycin: 0.077 ± 0.014 mg) (n = 4; t test; P = 0.605). Addi-
tionally, the rapamycin-treated cold-adapted mice displayed lower 
core body temperature, shown in Figure 3E.
Selective stimulation of adipose tissue by β3AR agonist. To more 
specifically activate βAR signaling only in adipose tissue, we used 
the well-established model of β3AR activation with the highly 
selective agonist CL316,243 (CL), in which chronic β3AR ago-
nist treatment leads to the robust browning of WAT that is often 
accompanied by increased energy expenditure and resistance to 
obesity and its metabolic complications (48–51). Mice received CL 
either with or without rapamycin for 1 week as detailed in Meth-
acute exposure period, detectable levels of beige adipocytes are not 
observed in WAT depots. However, following longer exposure times, 
the presence of these cells becomes quite evident (46, 47). Figure 3D 
shows that, after 7 days of cold exposure, the strong UCP1 expres-
sion in iBAT was unaffected by continuous rapamycin treatment, 
while the robust levels of UCP1 in iWAT were greatly diminished by 
rapamycin. Although there is no apparent difference in iBAT UCP1 
by Western blot between the vehicle and rapamycin groups, there 
nevertheless could be a net increase in total tissue mass and protein, 
including more overall UCP1 (42). However, the weights of the iBAT 
were not different between the groups (4°C saline: 0.085 ± 0.021 mg 
Figure 4. mTORC1 signaling participates in adipose browning induced by β3AR activation. Male mice (n = 5/group) were pretreated or not with rapamycin 
(Rapa; 2.5 mg/kg/BW) for 1 day, followed by daily treatment of either vehicle control, CL (1 mg/kg BW/day), CL with Rapa, or Rapa alone for 7 days. (A) Rep-
resentative images of the iBAT, iWAT, and gWAT tissues. (B) Histochemical staining by H&E (left panels) and UCP1 antisera (right panel) from iBAT, iWAT, and 
gWAT sections. (C) iBAT (20 μg protein; left panels), iWAT (30 μg protein; middle panels), and gWAT (50 μg protein; right panels) were analyzed by Western 
blotting for p-S6, p-AKT (S473) and total AKT, mitochondrial proteins UCP1, mitochondrial complex I component NDUFS4, and internal loading control β-actin.
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ods. Upon dissection, gross examination of the adipose tissues 
revealed noticeable differences among the treatment groups. Adi-
pose tissues from the CL-treated mice appeared to have a slightly 
darker complexion than those of the vehicle or rapamycin groups 
(Figure 4A). Histologically, CL treatment decreased lipid droplet 
size in iBAT and caused a substantial increase in multilocular adi-
pocytes within the iWAT, along with a robust increase in UCP1+ 
staining (Figure 4B). Rapamycin dramatically suppressed the 
numbers of UCP1-staining cells in iWAT, and rapamycin alone 
was observed to have no effect. In gWAT, a similar suppression of 
UCP1 by rapamycin was observed as in iWAT but to a lesser extent. 
Figure 4C presents Western blots showing that, similar to cold 
exposure, CL treatment led to rapamycin-sensitive S6 phospho-
rylation in all 3 adipose depots. iWAT exhibited the most robust 
increase in UCP1 expression, which was prevented by rapamycin. 
Levels of NDUFS4, a component of respiratory complex I, mea-
sured here as a surrogate indicator of mitochondrial mass, was 
also increased in a rapamycin-sensitive manner. This is consistent 
with the need for significant mitochondrial biogenesis to support 
the increased respiration and uncoupling that occurs in brown adi-
pocytes. In addition to Ucp1, peroxisome proliferation–activated 
nuclear receptor-α (PPARα), which is abundant in brown adipo-
cytes, was increased in iWAT and gWAT by CL treatment, as were 
a number of established PPARα gene targets involved in fatty acid 
Figure 5. Adipose-specific deletion of Raptor impairs brown/beige adipocytes during cold challenge. (A) Representative images of the iBAT, iWAT, and 
gWAT tissues from female floxed control (fl/fl) and adipose-specific Raptor KO (adKO). (B) Raptor, p-S6 and total S6, p-AKT (S473), total AKT, mitochon-
drial proteins UCP1, NDUFS4, COX4, endothelial marker VE-cadherin, and internal loading control GAPDH were detected by Western blotting in fat tissues 
of female Raptorfl/fl control and the adipose tissue–specific KO (adKO) at room temperature (RT) or cold exposure.
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oxidation. The same pattern was observed in iWAT and gWAT: 
increased by CL and essentially blocked by rapamycin (Supple-
mental Figure 7). Taken together, these data from cold exposure 
and CL treatment suggest that mTORC1 signaling is necessary for 
the browning of WAT.
Adipose-specific deletion of Raptor blocks acquisition of brown/
beige adipocytes. We generated mice with adipose-specific dele-
tion of Raptor by crossing Raptorfl/fl mice with adiponectin-Cre–
expressing mice. The Raptorfl/fl and Raptorfl/fl adiponectin-Cre 
(herein referred to as adKO) mice were subsequently subjected to 
a cold challenge. As reported earlier by Hall and colleagues (52), 
the adipose depots lacking RAPTOR were smaller in size (Figure 
5A). They also contained fully mature adipocytes and expressed 
adipogenic markers such as PPARγ2 and fatty acid binding pro-
tein 4 (aP2) (Supplemental Figure 8, A and B). Further analysis 
by Western blotting confirmed that Raptor was deleted in adi-
pose tissues (Figure 5B), while it remained intact in other tissues 
(not shown). As expected with a lack of RAPTOR, levels of p-S6 
were almost undetectable. For reasons that are unclear, total S6 
was also reduced in the Raptor-null adipose tissues, while total 
amounts of AKT and VE-cadherin were unchanged between 
control and adKO adipose tissues. Importantly, the response 
to the cold challenge was lost in the adKO adipose tissues. The 
levels of UCP1 and indicators of mitochondrial content such as 
NDUSF4 and COX4 were much lower in all adipose depots of 
the Raptor-null mice after chronic cold exposure, while another 
mitochondrial marker, ATP5A, was unchanged in these adipose 
tissues between the adKO and Raptorfl/fl control mice. We also 
noted that, unlike treating adult mice with rapamycin, there was 
a blunted response observed in iBAT of adKO mice. This is most 
Figure 6. PKA phosphorylates mTOR and Rap-
tor. (A and B) Schematic of mTOR (A) and RAP-
TOR (B) illustrate the domains and locations of 
candidate PKA sites. (C) myc-mTOR (left panel) 
and myc-RAPTOR (right panel) were transfected 
into HEK293 cells for 24 hours; myc-tagged pro-
teins were IP from cell lysates with anti–c-myc–
conjugated beads, washed twice with the lysis 
buffer, and incubated with PKA catalytic (cPKA) 
subunit, followed by Western blotting for PKA 
substrate and myc detection. (D) HEK293 cells 
transfected with myc-mTOR plasmid and treated 
24 hrs later with the PKA inhibitor H89 (15 μM) 
for 30 minutes, followed by Fsk (10 μM) or Iso (10 
μM) for 30 minutes treatment. Myc-mTOR was 
IP from cell lysates with anti–c-myc–conjugated 
beads, and Western blots were probed with 
PKA substrate antisera or anti-myc antisera as 
indicated. (E) HEK293 cells expressing myc-RAP-
TOR were treated and analyzed as in panel D. (F 
and G) HEK293 cells were transfected with either 
myc-mTOR plasmid (F) or myc-RAPTOR plasmid 
(G) and treated 24 hours later with Iso (1 μM) 
or Ins (100 nM) for 30 min, followed by process 
as in D. (H) HEK293 cells were transfected with 
myc-mTOR or triple Ser mutant (S3A: S1276A/
S1288A/S2112A), followed by the procedure as 
in C. (I) WT myc-mTOR or the S3A vector was 
expressed in HEK293 cells, treated as in D, and 
processed to measure PKA motif phospho-
rylation or myc as indicated. (J) HEK293 cells 
were transfected with myc-RAPTOR or S791A 
plasmid for 24 hrs and proceeded as in C. (K) WT 
myc-RAPTOR and the Ser mutants S791A and 
S791A/S792A were expressed in HEK293 cells, 
treated as in D, and processed to measure PKA 
motif phosphorylation or myc as indicated. The 
sample indicated as Iso* are nontransfected cells 
treated with Iso, revealing a nonspecific band (*). 
GAPDH served as loading input control.
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pressed by H89. Since cPKA can phosphorylate RAPTOR (Figure 6C), 
which is 150 kDa in size (54), we expressed myc-tagged RAPTOR in 
HEK293 cells and treated the cells with Fsk or Iso, with or without H89. 
Following IP of myc-RAPTOR and Western blotting with the PKA sub-
strate antibody, Fsk and Iso treatment induced robust phosphorylation 
of myc-RAPTOR (Figure 6E), which was blocked by H89 treatment. 
We compared Iso with Ins treatment and examined this phosphory-
lation. While Iso clearly increased the PKA-motif phosphorylation of 
mTOR (Figure 6F) and Raptor (Figure 6G), there was no such effect 
of Ins treatment. These results indicate that the mTORC1 components 
mTOR and RAPTOR can be directly phosphorylated by PKA.
We next mutated the 3 Ser in mTOR (S1276, S1288, and S2112) 
and the Ser in RAPTOR (S791) to Ala. First, shown in Figure 6H, 
the triple mutant of mTOR, designated as S3A, could no longer be 
phosphorylated in vitro by cPKA. Next, WT mTOR and the S3A 
mutant were introduced into HEK293 cells. Following treatment of 
the cells with Iso or Fsk for 30 minutes, mTOR was IP and analyzed 
for phosphorylation. Figure 6I shows that the S3A mutant of mTOR 
is refractory to the cAMP-elevating agents in cells. Second, in sharp 
contrast with WT RAPTOR, the Ser791A mutant could no longer 
be phosphorylated in vitro by cPKA (Figure 6J). We then compared 
the effects of WT RAPTOR and S791A RAPTOR in cells. In addi-
tion, although Ser792 is known to be an AMPK phosphorylation site 
likely because the deletion of Raptor occurs prenatally at the time 
the cells are becoming adipocytes during late gestation (53) and 
adiponectin-Cre begins to be expressed. This genetic evidence 
confirms a role for mTORC1 in the process of adipose browning 
and also suggests that there is a role for mTORC1 in the original 
development of the interscapular depot, which may or may not be 
dependent on PKA signaling.
mTOR and its component RAPTOR are phosphorylated by PKA
We next tested the possibility that mTORC1 might itself be a target of 
PKA. By inspecting the amino acid sequences of mTOR and RAPTOR 
across species, we indeed found that all mammalian mTOR proteins 
contain 3 strong and completely conserved RRXS motifs (Figure 6A) 
and that there is 1 motif in RAPTOR, as well (Figure 6B). Figure 6C 
shows that purified catalytic subunit of PKA (cPKA) can phosphory-
late mTOR and RAPTOR, detected with an antibody that recognizes 
phosphorylated Ser or Thr in the context of the RRXS/T motif. Next, 
we expressed a myc-tagged mTOR in HEK293 cells and treated these 
cells either with Fsk or Iso for 30 minutes in the presence or absence of 
H89. As shown in Figure 6D, both Fsk and Iso increased PKA-substrate 
motif phosphorylation of myc-mTOR, which was blocked by H89. Fig-
ure 6D also shows a heavily phosphorylated band of approximately 150 
kDa, which was also phosphorylated following PKA activation and sup-
Figure 7. Mutations of RAPTOR PKA site Ser791 have functional consequences for βAR signaling but not for Ins. (A) NIH3T3 cells were infected with 
lentivirus harboring mouse RAPTOR shRNA or scramble (Scr) control. Four days later, cells were lysed and assayed for endogenous RAPTOR and inter-
nal control GAPDH by immunoblotting. (B) NIH3T3 cells infected with lentivirus harboring RAPTOR shRNA were transfected with WT or S791A mutant 
myc-RAPTOR plasmid followed by either Iso (10 μM) or Ins (100 nM) treatment for 30 minutes. Phospho- and total S6K1 were measured by immunoblot-
ting. (C) HIB-1B cells stably expressing Flag-RAPTOR (WT or S791A) were differentiated and treated with Iso for 30 minutes, followed by anti-Flag IP. They 
were detected by PKA substrate and reprobed with anti-Flag. (D) Cells as in C were treated with Iso (1 μM) or Ins (10 nM) for 30 minutes. The lysates were 
detected by Western blotting for p-S6K1 and p-S6 and their respective total antibodies. GAPDH serves as loading control. (E) HIB-1B cells stably expressing 
myc-RAPTOR (WT or S791D) were pretreated with rapamycin (Rapa; 100 nM), followed by Iso (1 μM), for 1 hour and analyzed as in B. (F and G) Transcripts 
of Ppara in stably expressing RAPTOR (WT), S791A, and S791D were detected by qPCR (F), while Ucp1 was detected after 6 hours treatment by Iso (G) (100 
nM). One-way ANOVA followed by post-hoc group comparison tests; **P < 0.01. (In HIB-1B cells, endogenous RAPTOR still present.)
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transcripts were significantly lower. Together, these results argue 
for an important role of PKA phosphorylation of RAPTOR in the 
acquisition of the Ucp1-expressing cell phenotype.
Discussion
The SNS is well known to activate PKA through βARs not only for 
lipolysis and uncoupled respiration in brown adipocytes through 
UCP1, but also for increasing the net amount of browned adipo-
cytes present within white fat depots (8, 56–58). It has been repeat-
edly noted in laboratory animal models that the ability to gener-
ate these beige adipocytes is closely correlated with resistance to 
weight gain and preserved Ins sensitivity when challenged with a 
high-fat diet (48–50, 59–61). With the current intense interest in 
brown/beige adipose tissue in adult humans as a therapeutic tar-
get for increasing energy expenditure in metabolic disease, under-
standing the molecular events that drive their appearance and 
maintenance are critical. While the underlying cell lineage dis-
tinctions or molecular cues need further clarification (reviewed by 
ref. 62), increasing this UCP1-expressing adipocyte population is 
clearly a process that requires considerable synthetic and remod-
eling capacity within the tissue. This remodeling includes produc-
ing additional mitochondria and respiratory chain components, 
fatty acid oxidizing capacity, and, of course, UCP1. Here, we have 
shown that a direct signaling pathway from PKA to mTORC1 is 
involved in the β-adrenergic recruitment of these beige adipocytes 
in response to cold adaptation or to treatment with the β3AR ago-
nist CL. In addition, our studies in mice lacking RAPTOR in adipo-
cytes show impaired expression of UCP1 and other mitochondrial 
components, suggesting that there may be a role for mTORC1 
even in the early development of the iBAT depot.
We previously showed that, downstream of βARs and PKA, 
other kinases are activated in adipocytes, which together coordi-
nately maximize fuel metabolism. These kinases include ERK (39) 
to contribute to overall lipolysis (41), as well as p38 MAPK (40, 63). 
While these MAPKs, particularly p38, have an important func-
tional role for driving the transcription of the Ucp1 and Pgc1a genes 
(60, 63, 64), blockade of these MAPKs did not interfere with βAR 
activation of mTORC1. Instead, key components of mTORC1, 
specifically mTOR and RAPTOR, are directly phosphorylated by 
PKA. In mTOR, mutation of the 3 candidate PKA sites prevented 
its phosphorylation. Similarly, mutation of Ser791 in the RAPTOR 
PKA site eliminated its phosphorylation and functionally pre-
vented activation of S6K1 by Iso but not by Ins.
In addition to UCP1 and mitochondrial genes, key compo-
nents of the machinery necessary for the metabolic needs of 
brown and beige cells are also under the control of mTORC1. For 
example, PPARα is a master nuclear receptor for fatty acid β oxi-
dation, and PPARα has been shown to also participate in UCP1 
expression either directly or indirectly through ERRα (65–70). In 
addition, several downstream target genes of PPARα and ERRα 
are similarly under the control of mTORC1. These include Pdk4, 
Cpt1b, Fabp3, and Elovl3. Clearly, a number of molecular events 
are set in motion to achieve the complex cellular process of adi-
pose browning; some are dependent upon mTORC1, while others 
are not. Given that translational control is one of the hallmarks of 
biological regulation by mTOR (71), it would not be surprising if, 
along with direct transcriptional events, a layer of translational 
(55), some protein kinase substrate sequence prediction algorithms 
(e.g., Kinexus PhosphoNet) include Ser792 as a candidate PKA site. 
Therefore, we also generated the double-mutant S791A/S792A. 
All 3 of these myc-RAPTOR constructs (WT, S791A, and S791A/
S792A) were introduced into HEK293 cells and were subsequently 
treated with Iso or Fsk. Compared with the robustly phosphorylated 
WT myc-RAPTOR, phosphorylation was eliminated in the mutants 
(Figure 6K) to an equal degree. The residual phosphorylation that is 
seen is not RAPTOR, but rather is a protein that is slightly smaller 
than RAPTOR and is captured nonspecifically by myc antibody–
conjugated beads alone, since cells lacking a myc-RAPTOR con-
struct still contain this faint phosphorylated band. Since mutation 
of Ser791 to Ala already disrupted the PKA-dependent phosphory-
lation of RAPTOR, AMPK and Ser792 are unlikely to be involved 
in β-agonist–dependent phosphorylation of RAPTOR. From this 
series of experiments, we conclude that mTOR and RAPTOR are 
direct substrates of PKA.
Mutations of RAPTOR PKA site Ser791 have functional consequences 
for βAR signaling
To determine if phosphorylation of RAPTOR S791 is necessary for 
S6K1 activation mediated by βAR signaling, a lentivirus harboring 
RAPTOR shRNA was used to infect NIH3T3 cells in order to knock 
down endogenous RAPTOR, as shown in Figure 7A. Using this maneu-
ver, WT myc-RAPTOR or the S791A mutant myc-RAPTOR was intro-
duced into these RAPTOR knockdown cells, followed by treatment 
with either Iso or Ins to evaluate S6K1 activation. Figure 7B shows 
that S6K1 phosphorylation was abolished in response to Iso, while the 
Ins response remained comparable in both groups of cells. To next 
test whether phosphorylation of RAPTOR Ser791 conveys the signal 
originating from βAR action in adipocytes, we employed HIB-1B cells 
stably expressing Flag-tagged RAPTOR (WT) or S791A. As shown in 
Figure 7C, while Iso treatment led to WT RAPTOR phosphorylation, 
this phosphorylation was completely lost in the S791A mutant. Fig-
ure 7D shows that, similar to the NIH3T3 cell model in Figure 7B, Iso 
increased p-S6K1 as well as p-S6 in WT Raptor cells but not in RAP-
TOR S791A adipocytes, while the response to Ins remained unaf-
fected. Together, these results support the conclusion that mTOR and 
RAPTOR are targets of PKA and that their phosphorylation is neces-
sary to relay the signal from βARs to S6K1 activation.
To further test the functional consequences of RAPTOR phos-
phorylation at Ser791, a phosphomimetic RAPTOR was generated 
by changing Ser at 791 to Asp, and once again HIB-1B cells stably 
expressing myc-RAPTOR or the myc-RAPTOR S791D mutant 
were created. As shown in Figure 7E, even under basal conditions 
without the addition of Iso, levels of p-S6K1 and p-S6 tended to be 
higher in the cells expressing the S791D mutant. Provision of Iso 
increased their levels further. However, the more striking effect of 
the presence of RAPTOR S791D in these cells is shown in Figure 
7, F and G. Under basal conditions, the level of PPARα expression 
is massively increased (Figure 7F), and basal levels of Ucp1 tran-
scripts are 3-fold higher in S791D cells compared with WT cells 
(Figure 7G). Also shown in Figure 7G is that, when treated with 
Iso, Ucp1 transcripts were increased approximately 40-fold in 
WT cells, but in S791D cells, the increase over its basal level was 
an impressive 250-fold. In the S791A cells, Ppara was expressed 
at a comparable level to WT cells, but the Iso-stimulated Ucp1 
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growth and anabolic metabolism. When considered together, our 
findings suggest that the control of mTORC1 activity, and its contri-
butions to metabolic regulation, deserves fresh appraisal.
Methods
Reagents and antibodies. Iso, Fsk, Ins, dexamethasone (Dex), isobu-
tylmethylxanthine (IBMX), and the small molecule kinase inhibitors 
H89, SB, and PD were obtained from Sigma-Aldrich. The β3AR-selec-
tive agonist CL was a gift from Elliott Danforth Jr. (American Cyanamid 
Co., Pearl River, New York, USA). Rapamycin and torrin1 were from 
LC Laboratory. KT5720 was from Enzo Life Sciences. The protease 
inhibitor cocktail (complete Mini) and a phosphatase inhibitor cock-
tail (PhosSTOP) were from Roche Diagnostics. The following antisera 
were obtained from Cell Signaling Technology: p-S6 (Ser240/244, cata-
log 2215), total S6 (catalog 2217), p-S6K1(Thr389, catalog 9205), total 
S6K1 (catalog 9202), p-AKT (T308, catalog 9275), p-AKT (Ser473, cata-
log 4060), total AKT (catalog 9272), p-PRAS40 (Thr246, catalog 2640), 
total PRAS40 (catalog 2610), p-ULK1 (S757, catalog 6888), total ULK1 
(catalog 8054), p-ERK (Thr202/Tyr204, catalog 4370), total ERK(catalog 
9102), p38 MAPK(catalog 9202), p-GSK3 (S9 and S21, catalog 8566), 
total GSK3 (catalog 5676), phospho-RRXS/T motif antibody (PKA 
substrate, catalog 9624), RAPTOR (catalog 2280), RICTOR (catalog 
9476), “myc tag” (catalog 2272), COX4 (catalog 4844), and β-actin 
(catalog 4967). Other antisera used include UCP1 (catalog ab23841) 
and ATP5A (catalog ab14748) (both from Abcam). p-p38 MAPK (cata-
log ref-V121-A) and purified PKA catalytic subunit were ordered from 
Promega, plus NDUFS4 (Pierce Biotechnology, catalog PA5-21677), 
VE-cadherin (catalog sc-28644) and GAPDH (catalog sc-25788) (both 
from Santa Cruz Biotechnology). The EZview Red Anti–c-myc Affin-
ity Gel (catalog E6654) and the secondary antibodies conjugated with 
alkaline phosphatase (anti-rabbit, catalog A3687; anti-mouse, catalog 
A3562) were from Sigma-Aldrich.
Animal experiments. Male C57BL/6J mice were obtained from the 
Jackson Laboratory. Experiments were conducted in mice that were 
12–14 weeks of age. For the cold-challenge experiments, mice were 
administered rapamycin (5 mg/kg body weight [BW]/day) delivered in 
100 μl/20 g BW or vehicle (75% saline, 10% ethanol, 10% PEG300, 
5% Tween 80) (85) once a day for 2 consecutive days. On the third day, 
the mice were housed individually and placed at 4°C for up to 10 hours, 
with fresh bedding and free access to water. Control mice were main-
tained at room temperature (23°C). For chronic cold challenge, mice 
were placed at 4°C for 7 days with daily rapamycin (2.5 mg/kg BW/day) 
administration. For selective activation of β3AR, mice were injected i.p. 
with CL (1 mg/kg BW/day) (86, 87) with or without rapamycin (2.5 mg/
kg BW) for 1 week, after which they were euthanized, and iBAT, iWAT, 
and gWAT were dissected and immediately frozen in liquid nitrogen. 
Mice with a Raptorfl/fl allele (JAX-013188), as well as adiponectin-Cre 
(JAX-010803), were obtained from the Jackson Laboratory and bred to 
generate mice with a Raptor adipose–specific deletion. Tail DNA geno-
typing and Western blotting of lysate from adipose tissues, liver, and 
heart were used to confirm the specific deletion of Raptor in adipose.
Adipocyte cell culture. 3T3-L1 preadipocytes were obtained from 
ATCC. They were maintained and differentiated into adipocytes as 
described (88), with modifications (89). HEK293 cells were purchased 
from ATCC and cultured in DMEM with 10% FBS. Human primary 
s.c. adipocytes were provided by Zen-Bio. NIH3T3 cells were pur-
chased from ATCC and cultured in DMEM supplemented with 10% 
regulation turns out to be part of this mTORC1-driven effect on 
adipose tissue. This will be an important direction to explore in 
expanding these studies in the future.
The finding that PKA directly activates mTORC1 to drive adi-
pose browning is both unexpected and rather extraordinary for 
several reasons. First, Ins and catecholamines are best known for 
their ability to antagonize one another’s metabolic effects, yet Ins 
is a well-known activator of mTORC1 for promoting growth and 
energy storage. From much work conducted in this field, inhibit-
ing mTORC1 with rapamycin seems to be beneficial in terms of 
metabolism under some circumstances, but there are also com-
plications. For example, while mTORC1 inhibition with rapamy-
cin can increase longevity in mice (72, 73), chronic rapamycin 
treatment causes glucose intolerance and hyperlipidemia in both 
mice (74) and humans (75, 76); this appears to be caused by dis-
turbances in mTORC2 function (77). Mice with aP2-driven dele-
tion of Raptor in adipose tissue were reported to be resistant to 
diet- induced obesity, with smaller adipose tissue, increases in 
UCP1, and apparent improved Ins sensitivity (52, 78, 79). How-
ever, unlike our results described here, these earlier studies did 
not assess the effects of RAPTOR on the recruitment of brown 
adipocytes in response to cold or β-agonist stimulation. Impor-
tantly, the use of the aP2-Cre driver has subsequently been largely 
abandoned because it has been discovered that, in this animal, 
Cre recombinase can be expressed in other nonadipose tissues, 
including the brain, and other tissues during early development 
(64, 80, 81). Therefore, one cannot rule out the possibility that the 
loss of RAPTOR in some other tissue or cell type might contribute 
to the reported lean phenotype (52).
While it remains to be tested, our results here may contribute 
to understanding some other observations in the literature that 
suggest cAMP can activate mTORC1. For instance, thyroid-stim-
ulating hormone (TSH) has been reported to activate S6K1 in thy-
roid epithelia in a cAMP-dependent manner (82), and in pancre-
atic islets, GLP-1–dependent increases in cAMP — in the context 
of elevated glucose — were observed to activate S6K1 (83), which 
the authors concluded was due to cAMP-evoked intracellular Ca+2 
release. More recently, in a disease model of primary pigmented 
nodular adrenocortical disease (PPNAD), which inactivates the 
regulatory subunit of PKA, it was reported that mTORC1 activ-
ity was increased, resulting in prevention of apoptosis (84). In 2 
of these studies, the authors pointed to PRAS40 phosphorylation 
as a mediator, but whether this is the sole factor involved was 
not tested. In our studies here in adipocytes, phosphorylation of 
PRAS40 does not occur in response to β-agonists, thus eliminating 
it as a regulatory factor.
We believe that our study makes 2 important biological obser-
vations. First, that mTORC1 is a necessary component in the pro-
cess of the browning of white adipose depots. The second point is 
that there exists a signaling pathway from PKA to mTORC1 activa-
tion via direct phosphorylation of mTOR and RAPTOR. Given these 
findings and the ubiquitous expression of mTOR and PKA in many 
cell types, we speculate that this PKA-mTORC1 pathway may have 
broader significance by regulating a variety of cell signaling events 
in other tissues. Therefore, our studies illustrate that an inherently 
catabolic process of energy expenditure in adipose tissue utilizes 
what is most commonly considered to be the molecular driver of 
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resolved in 4%–20% Tris-glycine gels (Invitrogen) and transferred to 
nitrocellulose membranes (Bio-Rad) and incubated overnight at 4°C 
with specific primary antibodies. Secondary antisera conjugated with 
alkaline phosphatase were used for specific protein detection. To rep-
robe blots, membranes were stripped in buffer (62.5 mM Tris, 2% SDS, 
100 mM β-mercaptoethanol) at 37°C for 60 minutes. Image acquisi-
tion was performed on a Typhoon FLA 9000 imager (GE Healthcare), 
and data were analyzed using ImageQuant TL software.
RNA isolation and quantitative PCR. RNA from adipose tissues 
were first extracted by Trizol and purified by RNA mini-columns from 
QIAGEN. Reverse transcription and SYBR green quantitative PCR 
(qPCR; Invitrogen) were performed according to the manufacturer 
protocols. Target primer sequences are shown in Supplemental Table 1.
Tissue histology and microscopy. Adipose tissues were fixed with 
4% paraformaldehyde in PBS, dehydrated, embedded in paraffin, 
and sectioned (5-μm thickness). Sections were stained with H&E 
and examined under bright-field microscopy with a Nikon 80i. UCP1 
staining was performed as described previously (60, 93).
Statistics. All data are presented as mean ±SEM. Comparisons 
between groups were assessed by 1-way ANOVA with Tukey’s post-hoc 
test or unpaired Student’s t test (2-tailed) as indicated in figure legends.
Study approval. All animal experiments were approved by the San-
ford Burnham Prebys Medical Discovery Institute’s Institutional Ani-
mal Care and Use Committee in accordance with the 8th edition of the 
NIH Guide for the Care and Use of Laboratory Animals.
Note added in proof. While this manuscript was in press, an inde-
pendent report confirmed our finding of a positive role for mTORC1 
signaling in the browning of white fat (94).
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calf bovine serum. Prior to treatment, cells were washed twice with 
serum-free DMEM and maintained overnight in DMEM with 0.1% 
fatty-acid–free BSA cells. HIB-1B preadipocytes were cultured and dif-
ferentiated as described (87, 90). HIB-1B cells stably expressing RAP-
TOR WT, S791A (alanine) or S791D (aspartic acid) were generated as 
previously described (91, 92).
Plasmids and mutagenesis. The WT myc-mTOR and myc-RAPTOR 
mammalian expression vectors were from Addgene. To mutate candi-
date PKA sites in mTOR, the following primers were used to change the 
Ser residues to Ala: S2112A forward: 5′-TTC AGA CGG ATC GCC AAG 
CAG CTA-3′ and S2112A reverse: 5′-TAG CTG CTT GGC GAT CCG 
TCT GAA-3′; for S1276A/S1288A/S2112A triple mutation, the pair of 
primers forward: 5′-CTG CGA CGC TTG GCT CTG GAG CTG CTG 
AAG-3′ and reverse: 5′-CTT CAG CAG CTC CAG AGC CAA GCG 
TCG CAG-3′ was used and combined with 5′-GCC AGA AGG GTC 
GCC AAG GAC GAC TGG-3′. To mutate RAPTOR Ser791 to Ala, the 
primers were RAPTOR S791A forward: 5′-GAC AAG ATG CGC CGC 
GCC GCC TCC TAC TCC TCC CTC AAC TCC-3′ and RAPTOR S791A 
reverse: 5′-GGA GTT GAG GGA GTA GGA GGC GGC GCG GCG CAT 
CTT GTC. For the RAPTOR S791A/S792A mutation, forward: 5′-GAC 
AAG ATG CGC CGC GCC GCC GCC TAC TCC TCC CTC AAC TCC-
3′ and reverse: 5′-GGA GTT GAG GGA GGA GTA GGC GGC GGC 
GCGGCG CAT CTT GTC-3′. To mutate RAPTOR S791 to aspartic acid 
(S791D), we changed S791A forward primer from GCC to GAC, and 
the reverse primer GGC to GTC. PCR was performed according to the 
instructions of the QuickChange Multi Site-Directed Mutagenesis kit 
(Agilent Technologies) using WT myc-mTOR or RAPTOR as template. 
Mutations were all confirmed by DNA sequencing.
Transfection, IP, and Western blotting. Cells or tissues were lysed 
and sonicated in buffer containing 25 mM HEPES (pH 7.4), 150 mM 
NaCl, 5 mM EDTA, 5 mM EGTA, 5 mM glycerophosphate, 0.9% Tri-
ton X-100 (Sigma-Aldrich), 0.1% IGEPAL CA630, 5 mM sodium pyro-
phosphate, and 10% glycerol, plus 1 tablet each of complete protease 
inhibitor cocktail and PhoSTOP phosphatase inhibitors per 10 ml. For 
IP, HEK293 cells were transfected with myc-tagged mTOR or RAPTOR 
expression plasmid using lipofectamine 2000 (Invitrogen) according 
to the instructions provided. Cells were collected and lysed in the 
above buffer, and 2 mg total protein was incubated with anti–c-myc 
affinity gel overnight (Sigma-Aldrich). Beads were washed thoroughly 
in lysis buffer. For the in vitro PKA phosphorylation assay, 2 mg total 
protein was incubated with anti–c-myc affinity gel for 4 hours. Beads 
were washed twice with the lysis buffer and once with the PKA reac-
tion buffer (40 mM Tris-HCL [pH 7.4], 20 mM magnesium acetate, 0.2 
mM ATP), and PKA catalytic subunit was added to the beads. Protein 
phosphorylation by PKA was measured with PKA substrate antibody 
(phospho-RRXS/T motif antibody; Cell Signaling Technology). Flag-
tagged WT RAPTOR and the S791A mutant RAPTOR, or myc-tagged 
WT RAPTOR and S791D mutant, were introduced into HIB-1B cells, 
and single clones were selected with 5 μg/ml blastcidin for FLAG-RAP-
TOR cells or 100 μg/ml hygromycin for myc-RAPTOR cells to generate 
stable cell lines. Unless otherwise indicated, 50 μg total protein was 
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